The Effects of Dexmedetomidine on Postoperative Renal Function in Valvular Heart Surgery

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01886079

Enrollment

200

Registered

2013-06-25

Start date

2013-05-31

Completion date

2015-05-31

Last updated

2013-06-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Injury

Brief summary

The purpose of study is to compare the incidence of acute kidney injury in patients receiving perioperative dexmedetomidine or placebo undergoing valvular heart surgery.

Interventions

DRUGdexmedetomidine

0.4 mcg/kg/h, IV, The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery

DRUGSaline

0.4 mcg/kg/h, IV

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

20 Years to 90 Years

Healthy volunteers

Inclusion criteria

* adult patients over the age of 20 scheduled for valvular heart surgery

Exclusion criteria

* Left ventricular-ejection fraction \< 30% * Preexisting congestive heart failure * Severe coronary artery disease * Hemodynamically unstable arrhythmia * Cardiogenic shock during perioperative period * Ventricular assist device * Severe renal dysfunction (eGFR \< 15ml/min per 1.73m2)

Design outcomes

Primary

Measure	Time frame	Description
Comparison of postoperative renal function in patients with or without dexmedetomidine undergoing valvular heart surgery:	24 hours after surgery.	BUN/Creatinine, cystatin C, eGFR, urine output Incidence of acute kidney injury (based on the AKIN criteria)

Countries

South Korea

Contacts

Primary ContactJong Wook Song, MD

SJW72331@yuhs.ac82-2-2228-2420

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026